Trichlorethanol

Trichlorethanol

SCHEMBL325071

ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.OCC(Cl)(Cl)Cl

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 2/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trichlorethanol SCHEMBL7261325 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL291748 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL759616 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL1436780 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL8522341 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL16162174 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL4450822 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL88329 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL762332 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL6898269 1.00 LMNA (0.33) LMNATDP1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415468-B Electro-optical polymers 国立研究开发法人情报通信研究机构 2024-06-07 CN disclosed
WO-2024096067-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN 第一工業製薬株式会社 2024-05-10 WO disclosed
WO-2024096066-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE 第一工業製薬株式会社 2024-05-10 WO disclosed
US-20240150367-A1 NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2024-05-09 US disclosed
US-20240132492-A1 PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF JINAN UNIVERSITY (CN) 2024-04-25 US disclosed
CN-115348963-B Pyridopyrimidine compound and application thereof 暨南大学 2024-04-19 CN disclosed
WO-2024071370-A1 CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE 第一工業製薬株式会社 2024-04-04 WO disclosed
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND NISSAN CHEMICAL CORPORATION (JP) 2024-03-21 US disclosed
WO-2024029630-A1 CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION 第一工業製薬株式会社 2024-02-08 WO disclosed
EP-4310084-A1 PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF Jinan University (CN) 2024-01-24 EP disclosed
EP-0280894-A1 Novel antibiotic vermisporin, process for the production thereof and pharmaceutical composition comprising it as an active antibacterial agent MITSUBISHI KASEI CORPORATION (JP) 1988-09-07 EP disclosed
US-4675391-A IMMUNOREGULATORS KANTO ISHI PHARMACEUTICAL CO., LTD. (JP) 1987-06-23 US disclosed
EP-0213610-A1 Azetidin-2-one derivatives and process for production thereof LEDERLE (JAPAN) LTD. (JP) 1987-03-11 EP disclosed
EP-0206807-A2 Novel amino acid derivatives Kissei Pharmaceutical Co. Ltd. (JP) 1986-12-30 EP disclosed
EP-0194563-A2 Glycosides and process for preparation thereof MECT Corporation (JP) 1986-09-17 EP disclosed
EP-0181110-A2 Histidine derivatives as renin inhibitors Kissei Pharmaceutical Co. Ltd. (JP) 1986-05-14 EP disclosed
EP-0100104-A1 Muramyldipeptide derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1984-02-08 EP disclosed
US-4200573-A Derivatives of 3-carboxyrifamycin S and SV and process for their preparation ALFA FARMACEUTICI, S.P.A. (IT) 1980-04-29 US disclosed
US-4134980-A Phenylalkylamino-alkyl derivatives of quinazolinone and phthalazinone BOEHRINGER INGELHEIM GMBH (DE) 1979-01-16 US disclosed
US-3931196-A Phosphinolines and phosphindolines MONASH UNIVERSITY (AU) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132492-A1 PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF AKT3, AKT1S1, AKT2 LMNA 4085/4885TDP1 1058/4885TP53 118/4885
US-20240150367-A1 NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF REN, PKD1, NPR1 LMNA 4098/4885TDP1 4671/4885TP53 1064/4885
US-20240092784-A1 CONDENSED HETEROCYCLIC COMPOUND SPR, QDPR, SUCNR1 LMNA 2911/4885TDP1 1193/4885TP53 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.